Parallel imports are a non-issue. It's not possible to import iPPS from a different country without the requisite approvals and documentation. It's also easier to track, making it easier to sue those who import the drug. There are tight restrictions in place when it comes to importing pharmaceutical products, so it's a non-starter for me.
If iPPS is shown to be disease modifying then I can easily see it receiving between 4-6k and becoming a market leader. That is, however, with the right people negotiating and marketing the drug. I can see a regional deal with China being signed this year for OA, MPS on the other will be complicated by possible pricing. My views only.
Ann: Paradigm AGM Presentation, page-51
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 33682 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |